Stoke Therapeutics, Inc. - 8-K Filing
Stoke Therapeutics held its 2026 Annual Meeting of Stockholders on June 3, 2026, where three Class I directors were elected: G. Clare Kahn, Ph.D., Adrian Krainer, Ph.D., and Julie Anne Smith. The stockholders also ratified the appointment of Ernst & Young LLP as their independent registered public accounting firm for fiscal year ending December 31, 2026, and approved on a non-binding advisory basis the compensation of named executive officers. (Items: 5.07 Submission of Matters to a Vote of Security Holders)
Tickers: $STOK